Responses

Download PDFPDF
Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Re:Comment on: Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study

    Dear Editor,

    We would like to thank Dr. Uzun and Dr. Pehlivan for showing interest in our study.[1] It is well-known that various factors may influence choroidal thickness. In our study,[1] there was no significant difference in the age, sex, spherical equivalents, and incidence of diabetes mellitus and hypertension between the ranibizumab and aflibercept groups. As mentioned, the limitation of our retrospective...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Comment on: Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study
    • Salih Uzun, M.D., Ophthalmologist
    • Other Contributors:
      • Emre Pehlivan

    Dear Editor,

    We have read and reviewed the article entitled as "Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study'' by Kim et al. with interest.1 The authors analyzed 240 eyes of 240 treatment-naive neovascular AMD patients who treated with three-monthly injections of either ranibizumab (ranibizumab group) or aflibercept (aflibercept group). Th...

    Show More
    Conflict of Interest:
    None declared.